These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
510 related articles for article (PubMed ID: 31515284)
1. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Lee TD; Lee OW; Brimacombe KR; Chen L; Guha R; Lusvarghi S; Tebase BG; Klumpp-Thomas C; Robey RW; Ambudkar SV; Shen M; Gottesman MM; Hall MD Mol Pharmacol; 2019 Nov; 96(5):629-640. PubMed ID: 31515284 [TBL] [Abstract][Full Text] [Related]
2. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity. Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785 [TBL] [Abstract][Full Text] [Related]
3. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice. Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694 [TBL] [Abstract][Full Text] [Related]
4. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening. Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191 [TBL] [Abstract][Full Text] [Related]
5. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). Kannan P; Telu S; Shukla S; Ambudkar SV; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD ACS Chem Neurosci; 2011 Feb; 2(2):82-9. PubMed ID: 22778859 [TBL] [Abstract][Full Text] [Related]
6. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Shukla S; Robey RW; Bates SE; Ambudkar SV Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320 [TBL] [Abstract][Full Text] [Related]
7. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells. Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476 [TBL] [Abstract][Full Text] [Related]
8. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2). Chen X; Unadkat JD; Mao Q Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138 [TBL] [Abstract][Full Text] [Related]
9. CC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance. Beebe J; Zhang JT J Pharmacol Exp Ther; 2019 Nov; 371(2):320-326. PubMed ID: 31455631 [TBL] [Abstract][Full Text] [Related]
10. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357 [TBL] [Abstract][Full Text] [Related]
11. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators. Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123 [TBL] [Abstract][Full Text] [Related]
12. Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference. Ansbro MR; Shukla S; Ambudkar SV; Yuspa SH; Li L PLoS One; 2013; 8(4):e60334. PubMed ID: 23593196 [TBL] [Abstract][Full Text] [Related]
13. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Zhou SF Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431 [TBL] [Abstract][Full Text] [Related]
14. An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus. Han LW; Gao C; Mao Q Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):817-829. PubMed ID: 30010462 [TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210 [TBL] [Abstract][Full Text] [Related]
16. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Crivori P; Reinach B; Pezzetta D; Poggesi I Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367 [TBL] [Abstract][Full Text] [Related]
17. ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461. de Gooijer MC; Buil LCM; Çitirikkaya CH; Hermans J; Beijnen JH; van Tellingen O Mol Pharm; 2018 Nov; 15(11):5236-5243. PubMed ID: 30252484 [TBL] [Abstract][Full Text] [Related]
18. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier. Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells. Saeed MEM; Boulos JC; Elhaboub G; Rigano D; Saab A; Loizzo MR; Hassan LEA; Sugimoto Y; Piacente S; Tundis R; Yagi S; Khalid H; Efferth T Phytomedicine; 2019 Sep; 62():152945. PubMed ID: 31132750 [TBL] [Abstract][Full Text] [Related]
20. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents. Sampson A; Peterson BG; Tan KW; Iram SH Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]